HRP20230628T1 - Primjena i doziranje diaminofenotiazina - Google Patents
Primjena i doziranje diaminofenotiazina Download PDFInfo
- Publication number
- HRP20230628T1 HRP20230628T1 HRP20230628TT HRP20230628T HRP20230628T1 HR P20230628 T1 HRP20230628 T1 HR P20230628T1 HR P20230628T T HRP20230628T T HR P20230628TT HR P20230628 T HRP20230628 T HR P20230628T HR P20230628 T1 HRP20230628 T1 HR P20230628T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- use according
- image
- disorder
- dementia
- Prior art date
Links
- KPYHKEZPEDJERZ-UHFFFAOYSA-N 10h-phenothiazine-1,2-diamine Chemical class C1=CC=C2NC3=C(N)C(N)=CC=C3SC2=C1 KPYHKEZPEDJERZ-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 34
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 9
- 208000035475 disorder Diseases 0.000 claims 9
- 239000002253 acid Substances 0.000 claims 8
- 238000011282 treatment Methods 0.000 claims 6
- SPCMQFLNOVTUBM-UHFFFAOYSA-N [7-(dimethylazaniumyl)-10h-phenothiazin-3-yl]-dimethylazanium;methanesulfonate Chemical compound CS([O-])(=O)=O.CS([O-])(=O)=O.C1=C([NH+](C)C)C=C2SC3=CC([NH+](C)C)=CC=C3NC2=C1 SPCMQFLNOVTUBM-UHFFFAOYSA-N 0.000 claims 5
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 claims 4
- 206010012289 Dementia Diseases 0.000 claims 4
- 229940099433 NMDA receptor antagonist Drugs 0.000 claims 4
- 150000007513 acids Chemical class 0.000 claims 4
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 4
- 239000000544 cholinesterase inhibitor Substances 0.000 claims 4
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 claims 4
- 208000011580 syndromic disease Diseases 0.000 claims 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 206010059245 Angiopathy Diseases 0.000 claims 2
- 102000014461 Ataxins Human genes 0.000 claims 2
- 108010078286 Ataxins Proteins 0.000 claims 2
- 206010003694 Atrophy Diseases 0.000 claims 2
- 208000014644 Brain disease Diseases 0.000 claims 2
- 208000029402 Bulbospinal muscular atrophy Diseases 0.000 claims 2
- 206010008025 Cerebellar ataxia Diseases 0.000 claims 2
- 208000004051 Chronic Traumatic Encephalopathy Diseases 0.000 claims 2
- 208000011990 Corticobasal Degeneration Diseases 0.000 claims 2
- 206010067889 Dementia with Lewy bodies Diseases 0.000 claims 2
- 201000010374 Down Syndrome Diseases 0.000 claims 2
- 208000032274 Encephalopathy Diseases 0.000 claims 2
- 208000002339 Frontotemporal Lobar Degeneration Diseases 0.000 claims 2
- 208000023105 Huntington disease Diseases 0.000 claims 2
- 208000027747 Kennedy disease Diseases 0.000 claims 2
- 201000002832 Lewy body dementia Diseases 0.000 claims 2
- 208000001089 Multiple system atrophy Diseases 0.000 claims 2
- 206010068871 Myotonic dystrophy Diseases 0.000 claims 2
- 208000010577 Niemann-Pick disease type C Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 208000027089 Parkinsonian disease Diseases 0.000 claims 2
- 206010034010 Parkinsonism Diseases 0.000 claims 2
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims 2
- 208000025820 Sanfilippo syndrome type B Diseases 0.000 claims 2
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 claims 2
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 claims 2
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 claims 2
- 208000007930 Type C Niemann-Pick Disease Diseases 0.000 claims 2
- 230000037444 atrophy Effects 0.000 claims 2
- 201000004562 autosomal dominant cerebellar ataxia Diseases 0.000 claims 2
- 230000002490 cerebral effect Effects 0.000 claims 2
- 210000000349 chromosome Anatomy 0.000 claims 2
- 230000007850 degeneration Effects 0.000 claims 2
- 208000017004 dementia pugilistica Diseases 0.000 claims 2
- 239000008187 granular material Substances 0.000 claims 2
- 210000003000 inclusion body Anatomy 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 208000036709 mucopolysaccharidosis type 3B Diseases 0.000 claims 2
- 208000012227 mucopolysaccharidosis type IIIB Diseases 0.000 claims 2
- 230000001537 neural effect Effects 0.000 claims 2
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims 2
- RBTBFTRPCNLSDE-UHFFFAOYSA-N 3,7-bis(dimethylamino)phenothiazin-5-ium Chemical compound C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 RBTBFTRPCNLSDE-UHFFFAOYSA-N 0.000 claims 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 1
- 208000032859 Synucleinopathies Diseases 0.000 claims 1
- 102100040347 TAR DNA-binding protein 43 Human genes 0.000 claims 1
- 101710150875 TAR DNA-binding protein 43 Proteins 0.000 claims 1
- 208000036278 TDP-43 proteinopathy Diseases 0.000 claims 1
- 208000034799 Tauopathies Diseases 0.000 claims 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 150000007520 diprotic acids Chemical class 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical class OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 claims 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical class CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 claims 1
- 150000007522 mineralic acids Chemical class 0.000 claims 1
- 150000007518 monoprotic acids Chemical class 0.000 claims 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical class C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 230000000626 neurodegenerative effect Effects 0.000 claims 1
- 150000007524 organic acids Chemical class 0.000 claims 1
- 125000005489 p-toluenesulfonic acid group Chemical class 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229920000155 polyglutamine Polymers 0.000 claims 1
- 108010040003 polyglutamine Proteins 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 230000004845 protein aggregation Effects 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/20—Agglomerating; Granulating; Tabletting
- A23P10/28—Tabletting; Making food bars by compression of a dry powdered mixture
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/30—Encapsulation of particles, e.g. foodstuff additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D75/00—Packages comprising articles or materials partially or wholly enclosed in strips, sheets, blanks, tubes, or webs of flexible sheet material, e.g. in folded wrappers
- B65D75/28—Articles or materials wholly enclosed in composite wrappers, i.e. wrappers formed by associating or interconnecting two or more sheets or blanks
- B65D75/30—Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding
- B65D75/32—Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding one or both sheets or blanks being recessed to accommodate contents
- B65D75/36—Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding one or both sheets or blanks being recessed to accommodate contents one sheet or blank being recessed and the other formed of relatively stiff flat sheet material, e.g. blister packages, the recess or recesses being preformed
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D2203/00—Decoration means, markings, information elements, contents indicators
- B65D2203/02—Labels
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Mycology (AREA)
- Psychology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Mechanical Engineering (AREA)
- Botany (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Composite Materials (AREA)
- Physiology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
Claims (21)
1. Spoj koji sadrži metiltioninij („MT“), naznačen time, da je za uporabu u postupku terapijskog ili profilaktičkog liječenja neurodegenerativnog poremećaja agregacije proteina kod pojedinca,
pri čemu taj postupak obuhvaća oralnu primjenu jednom dnevno navedenom pojedincu navedenog spoja koji sadrži MT,
gdje spomenuta primjena osigurava pojedincu na dan, ukupnu dnevnu dozu od između 0,5 i 20 mg spoja MT,
pri čemu spoj je spoj predstavljen sljedećom formulom („LMTX“):
[image]
u kojoj svaka od HnA i HnB (gdje su prisutne) jesu protičke kiseline koje mogu biti iste ili različite,
dok p = 1 ili 2; q = 0 ili 1; n = 1 ili 2; (p + q) x n = 2,
i pri čemu se navedeni neurodegenerativni poremećaj bira iz sljedećeg popisa koji sačinjavaju:
Alzheimerova bolest;
Pickova bolest, progresivna supranuklearna paraliza, frontotemporalna demencija (FTD), FTD s parkinsonizmom koji je povezan s kromosomom 17, sindromi frontotemporalne lobarne degeneracije; disinhibicija-demencija-parkinsonizam-amiotrofija-kompleks, palido-ponto-nigralna degeneracija, Guam-ALS-sindrom, palido-nigro lujzijanska degeneracija, kortikobazalna degeneracija, demencija s argirofilnim zrncima, pugilistička demencija ili kronična traumatska encefalopatija, Downov sindrom, subakutni sklerozirajući panencefalitis, Niemann-Pickova bolest tipa C, Sanfilippov sindrom tipa B, ili miotonična distrofija DM1 ili DM2;
Huntingtonova bolest, spinalna bulbarna mišićna atrofija, dentatorubropalidolujzijanska atrofija ili spinocerebelarna ataksija;
TDP-43 proteinopatija koja je FTLD-TDP;
Parkinsonova bolest, demencija s Lewyjevim tjelešcima i multipla sistemska atrofija;
nasljedna cerebralna angiopatija;
amiotrofična lateralna skleroza; i
porodična encefalopatija s neuronskim inkluzijskim tijelima.
2. Spoj MT za uporabu prema patentnom zahtjevu 1, naznačen time, da ukupna dnevna doza iznosi od 2 do 15 mg; ili od 3 do 10 mg.
3. Spoj MT za uporabu prema patentnom zahtjevu 1 ili zahtjevu 2, naznačen time, da:
(a) spoj ima sljedeću formulu, gdje su HA i HB različite monoprotičke kiseline:
[image]
ili
(b) spoj ima sljedeću formulu:
[image]
u kojoj svaka od HnX je protička kiselina, ili
(c) spoj ima sljedeću formulu i H2A je diprotička kiselina:
[image]
.
4. Spoj MT za uporabu prema patentnom zahtjevu 3, naznačen time, da spoj ima sljedeću formulu i on je bis-monoprotička kiselina:
[image]
.
5. Spoj MT za uporabu prema bilo kojem od patentnih zahtjeva 1 do 4, naznačen time, da protička kiselina ili svaka od protičkih kiselina je anorganska kiselina.
6. Spoj MT za uporabu prema bilo kojem od patentnih zahtjeva 1 do 4, naznačen time, da protička kiselina ili svaka od protičkih kiselina je organska kiselina.
7. Spoj MT za uporabu prema patentnom zahtjevu 6, naznačen time, da se protička kiselina ili svaka od protičkih kiselina bira od H2CO3; CH3COOH; metansulfonske kiseline, 1,2-etandisulfonske kiseline, etansulfonske kiseline, naftalendisulfonske kiseline, p-toluensulfonske kiseline.
8. Spoj MT za uporabu prema patentnom zahtjevu 7, naznačen time, da spoj je LMTM:
[image]
.
9. Spoj MT za uporabu prema patentnom zahtjevu 8, naznačen time, da ukupna dnevna doza spoja LMTM iznosi oko 0,8 do 33 mg na dan, još poželjnije od 6 do 12 mg na dan ukupnog LMTM.
10. Spoj MT za uporabu prema patentnom zahtjevu 7, naznačen time, da se spoj bira iz sljedećeg popisa koji sačinjavaju:
[image]
[image]
[image]
[image]
[image]
[image]
.
11. Spoj MT za uporabu prema bilo kojem od patentnih zahtjeva 1 do 10, naznačen time, da pojedinac u povijesti bolesti nije primao liječenje s inhibitorom acetilkolinesteraze ili antagonistom receptora N-metil-D-aspartata.
12. Spoj MT za uporabu prema bilo kojem od patentnih zahtjeva 1 do 10, naznačen time, da je pojedinac u povijesti bolesti primao liječenje s inhibitorom acetilkolinesteraze i/ili antagonistom receptora N-metil-D-aspartata, ali da je prestao uzimati taj lijek najmanje 1, 2, 3, 4, 5, 6, 7 ili 8 tjedana prije liječenja sa spojem koji sadrži MT.
13. Spoj MT za uporabu prema bilo kojem od patentnih zahtjeva 1 do 10, naznačen time, da je pojedinac odabran kao onaj koji je primao liječenje s inhibitorom acetilkolinesteraze i/ili antagonistom receptora N-metil-D-aspartata, pri čemu je navedeno liječenje s inhibitorom acetilkolinesteraze i/ili antagonistom receptora N-metil-D-aspartata, prekinuto prije liječenja sa spojem koji sadrži MT.
14. Spoj MT za uporabu prema bilo kojem od patentnih zahtjeva 1 do 13, naznačen time, da poremećaj je tauopatija.
15. Spoj MT za uporabu prema bilo kojem od patentnih zahtjeva 1 do 13, naznačen time, da se poremećaj bira iz sljedećeg popisa koji sačinjavaju:
Pickova bolest, progresivna supranuklearna paraliza, frontotemporalna demencija, FTD s parkinsonizmom koji je povezan s kromosomom 17, sindromi frontotemporalne lobarne degeneracije; disinhibicija-demencija-parkinsonizam-amiotrofija-kompleks, palido-ponto-nigralna degeneracija, Guam-ALS-sindrom, palido-nigro lujzijanska degeneracija, kortikobazalna degeneracija, demencija s argirofilnim zrncima, pugilistička demencija ili kronična traumatska encefalopatija, Downov sindrom, subakutni sklerozirajući panencefalitis, Niemann-Pickova bolest tipa C, Sanfilippov sindrom tipa B, ili miotonična distrofija DM1 ili DM2.
16. Spoj MT za uporabu prema bilo kojem od patentnih zahtjeva 1 do 14, naznačen time, da poremećaj je Alzheimerova bolest.
17. Spoj MT za uporabu prema bilo kojem od patentnih zahtjeva 1 do 13, naznačen time, da poremećaj je poliglutaminski poremećaj koji je opcionalno Huntingtonova bolest, spinalna bulbarna mišićna atrofija, dentatorubropalidolujzijanska atrofija ili spinocerebelarna ataksija.
18. Spoj MT za uporabu prema bilo kojem od patentnih zahtjeva 1 do 13, naznačen time, da poremećaj je TDP-43 proteionopatija koja je opcionalno FTLD-TDP.
19. Spoj MT za uporabu prema bilo kojem od patentnih zahtjeva 1 do 13, naznačen time, da poremećaj je sinukleinopatija koja se opcionalno bira od Parkinsonove bolesti, demencije s Lewyjevim tjelešcima i multiple sistemske atrofije.
20. Spoj MT za uporabu prema bilo kojem od patentnih zahtjeva 1 do 13, naznačen time, da se poremećaj bira od nasljedne cerebralne angiopatije, amiotrofične lateralne skleroze, ili porodične encefalopatije s neuronskim inkluzijskim tijelima.
21. Farmaceutski pripravak, naznačen time, da sadrži spoj MT i farmaceutski prihvatljiv nosač ili razrjeđivač, u obliku jedinice za doziranje, pri čemu pripravak sadrži bilo koji iznos od 1,5, 2, 2,5, 3, 3,5, 4, 5, 6, 7, 8, 9, 10, 15, 16, 17 ili 18 mg od LMTM:
[image]
.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1612863.9A GB201612863D0 (en) | 2016-07-25 | 2016-07-25 | Administration and dosage of diaminophenothiazines |
| GBGB1710382.1A GB201710382D0 (en) | 2017-06-29 | 2017-06-29 | Administration and dosage of Diaminophenothiazines |
| EP17743330.7A EP3487505B1 (en) | 2016-07-25 | 2017-07-25 | Administration and dosage of diaminophenothiazines |
| PCT/EP2017/068749 WO2018019823A1 (en) | 2016-07-25 | 2017-07-25 | Administration and dosage of diaminophenothiazines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20230628T1 true HRP20230628T1 (hr) | 2023-09-29 |
Family
ID=59399428
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20230628TT HRP20230628T1 (hr) | 2016-07-25 | 2017-07-25 | Primjena i doziranje diaminofenotiazina |
Country Status (18)
| Country | Link |
|---|---|
| US (4) | US11065256B2 (hr) |
| EP (3) | EP4335517A2 (hr) |
| JP (1) | JP7073330B2 (hr) |
| KR (4) | KR20230058533A (hr) |
| CN (2) | CN109789148A (hr) |
| AU (3) | AU2017301966B2 (hr) |
| CA (1) | CA3031578A1 (hr) |
| DK (1) | DK3487505T3 (hr) |
| ES (1) | ES2946165T3 (hr) |
| FI (1) | FI3487505T3 (hr) |
| HR (1) | HRP20230628T1 (hr) |
| MX (2) | MX2019000946A (hr) |
| MY (1) | MY201804A (hr) |
| PL (1) | PL3487505T3 (hr) |
| PT (1) | PT3487505T (hr) |
| SG (1) | SG11201900228YA (hr) |
| SI (1) | SI3487505T1 (hr) |
| WO (1) | WO2018019823A1 (hr) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3121169T3 (pl) | 2006-07-11 | 2022-05-23 | Wista Laboratories Ltd. | Sposoby syntezy i/lub oczyszczania związków diaminofenotiazyniowych |
| SG11201900228YA (en) * | 2016-07-25 | 2019-02-27 | Wista Lab Ltd | Administration and dosage of diaminophenothiazines |
| CN112805008A (zh) | 2018-07-26 | 2021-05-14 | 维斯塔实验室有限公司 | 在群体中最优的二氨基吩噻嗪剂量 |
| US20210193322A1 (en) | 2018-09-05 | 2021-06-24 | Genting Taurx Diagnostic Centre Sdn Bhd | Network methods for neurodegenerative diseases |
| KR20210150502A (ko) * | 2019-04-10 | 2021-12-10 | 젠팅 타우알엑스 다이어그노스틱 센터 에스디엔 비에이치디 | 적응적인 신경학적 검사 방법 |
| GB201909454D0 (en) | 2019-07-01 | 2019-08-14 | Wista Lab Ltd | Enhancers |
| GB201909493D0 (en) | 2019-07-01 | 2019-08-14 | Wista Lab Ltd | Therapeutic interactions |
| GB201909506D0 (en) | 2019-07-02 | 2019-08-14 | Wista Lab Ltd | Synaptopathies |
| GB202006659D0 (en) | 2020-05-05 | 2020-06-17 | Wista Lab Ltd | Therapeutic treatments |
| MX2022013884A (es) * | 2020-05-05 | 2022-11-30 | Wista Lab Ltd | Compuestos de metiltioninio para usarse en el tratamiento de hipoxemia. |
| WO2023232764A1 (en) | 2022-05-31 | 2023-12-07 | Wista Laboratories Ltd. | Treatment of neurodegenerative disorders utilising methylthioninium (mt)-containing compounds |
| WO2024063700A1 (en) | 2022-09-21 | 2024-03-28 | Yin Sze Loh | Oral formulation of diaminophenothiazines and methods of making and using the same in the treatment and/or prevention of diseases |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9506197D0 (en) | 1995-03-27 | 1995-05-17 | Hoffmann La Roche | Inhibition of tau-tau association. |
| GB0101049D0 (en) | 2001-01-15 | 2001-02-28 | Univ Aberdeen | Materials and methods relating to protein aggregation in neurodegenerative disease |
| HUE044355T2 (hu) | 2004-09-23 | 2019-10-28 | Wista Lab Ltd | Eljárások diaminofenotiazínium vegyületek, többek között metiltionínium-klorid (MTC) kémiai szintézisére és tisztítására |
| AU2007231124B2 (en) * | 2006-03-29 | 2013-02-21 | Wista Laboratories Ltd. | 3,7-diamino-10H-phenothiazine salts and their use |
| CN101460157B (zh) * | 2006-03-29 | 2015-09-02 | 维斯塔实验室有限公司 | 蛋白聚集抑制剂 |
| SI2853293T1 (en) | 2006-03-29 | 2018-03-30 | Wista Laboratories Ltd. | Tioninium compounds and their use |
| PL3121169T3 (pl) | 2006-07-11 | 2022-05-23 | Wista Laboratories Ltd. | Sposoby syntezy i/lub oczyszczania związków diaminofenotiazyniowych |
| FR2903696B1 (fr) | 2006-07-12 | 2011-02-11 | Provence Technologies | Procede de purification de composes diaminophenothiazium |
| EP2167095B1 (en) * | 2007-06-19 | 2019-05-29 | WisTa Laboratories Ltd. | Phenothiazine compounds for treating mild cognitive impairment |
| MY161656A (en) * | 2007-10-03 | 2017-04-28 | Wista Lab Ltd | Therapeutic use of diaminophenothiazines |
| WO2010078659A1 (en) | 2009-01-12 | 2010-07-15 | Foster Health Inc. | Compositions and methods for nutritional prevention and treatment of alzheimer's-associated conditions |
| WO2011036561A2 (en) | 2009-09-24 | 2011-03-31 | Wis Ta Laboratories Ltd. | Process |
| WO2011036558A2 (en) | 2009-09-24 | 2011-03-31 | Wista Laboratories Ltd. | Crystalline methylthionium chloride (methylene blue) hydrates |
| AU2011334679B2 (en) | 2010-11-30 | 2016-12-15 | Wista Laboratories Ltd. | Formulations comprising methylthioninium chloride |
| MY165906A (en) * | 2011-02-11 | 2018-05-18 | Wista Lab Ltd | Phenothiazine diaminium salts and their use |
| SG11201900228YA (en) * | 2016-07-25 | 2019-02-27 | Wista Lab Ltd | Administration and dosage of diaminophenothiazines |
| CN112805008A (zh) | 2018-07-26 | 2021-05-14 | 维斯塔实验室有限公司 | 在群体中最优的二氨基吩噻嗪剂量 |
-
2017
- 2017-07-25 SG SG11201900228YA patent/SG11201900228YA/en unknown
- 2017-07-25 KR KR1020237013185A patent/KR20230058533A/ko not_active IP Right Cessation
- 2017-07-25 ES ES17743330T patent/ES2946165T3/es active Active
- 2017-07-25 KR KR1020197005446A patent/KR102475825B1/ko active IP Right Grant
- 2017-07-25 CA CA3031578A patent/CA3031578A1/en active Pending
- 2017-07-25 AU AU2017301966A patent/AU2017301966B2/en active Active
- 2017-07-25 CN CN201780058028.2A patent/CN109789148A/zh active Pending
- 2017-07-25 EP EP23212899.1A patent/EP4335517A2/en active Pending
- 2017-07-25 EP EP23165202.5A patent/EP4223297A3/en active Pending
- 2017-07-25 WO PCT/EP2017/068749 patent/WO2018019823A1/en unknown
- 2017-07-25 PT PT177433307T patent/PT3487505T/pt unknown
- 2017-07-25 DK DK17743330.7T patent/DK3487505T3/da active
- 2017-07-25 CN CN202310423724.6A patent/CN116531386A/zh active Pending
- 2017-07-25 US US16/320,148 patent/US11065256B2/en active Active
- 2017-07-25 PL PL17743330.7T patent/PL3487505T3/pl unknown
- 2017-07-25 MX MX2019000946A patent/MX2019000946A/es unknown
- 2017-07-25 HR HRP20230628TT patent/HRP20230628T1/hr unknown
- 2017-07-25 FI FIEP17743330.7T patent/FI3487505T3/fi active
- 2017-07-25 MY MYPI2019000171A patent/MY201804A/en unknown
- 2017-07-25 JP JP2019501700A patent/JP7073330B2/ja active Active
- 2017-07-25 KR KR1020247016105A patent/KR20240074909A/ko not_active Application Discontinuation
- 2017-07-25 EP EP17743330.7A patent/EP3487505B1/en active Active
- 2017-07-25 SI SI201731376T patent/SI3487505T1/sl unknown
- 2017-07-25 KR KR1020227042657A patent/KR102592614B1/ko active IP Right Grant
-
2019
- 2019-01-22 MX MX2021009899A patent/MX2021009899A/es unknown
-
2021
- 2021-06-16 US US17/349,427 patent/US11759469B2/en active Active
-
2022
- 2022-10-07 US US17/961,765 patent/US20230165877A1/en active Pending
- 2022-12-19 AU AU2022291420A patent/AU2022291420B2/en active Active
-
2023
- 2023-04-06 US US18/131,570 patent/US20230346794A1/en active Pending
- 2023-05-17 AU AU2023203084A patent/AU2023203084A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20230628T1 (hr) | Primjena i doziranje diaminofenotiazina | |
| CL2010001467A1 (es) | Compuestos derivados de fenil-imidazol sustituido con un heteroaromatico biciclico; composicion farmaceutica que los comprende; y su uso como inhibidores de la pde10a para tratar trastornos neurodegenerativos o psiquiatricos como alzheimer, demencia alcoholica, trastorno del aprendizaje, esquizofrenia, adiccion a las drogas. | |
| ATE502017T1 (de) | Pyrazolderivate als p2x7-modulatoren | |
| WO2018042362A9 (en) | Muscarinic m1 receptor positive allosteric modulators | |
| IL288375A (en) | New compounds and their pharmaceutical preparations for the treatment of diseases | |
| WO2008119685A3 (en) | Oxazolidine and morpholine carboxamide derivatives as p2x7 modulators | |
| PH12019500036A1 (en) | Heterocyclic compound used as fgfr inhibitor | |
| EP3941462A4 (en) | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT-MEDIED DISEASES | |
| IL282163A (en) | A pharmaceutical preparation for oral administration containing an aminopyrimidine derivative or its salt | |
| GB201911868D0 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | |
| MX2013006768A (es) | Moduladores de receptor de glucagon. | |
| IL290472A (en) | An oral pharmaceutical preparation that includes a heterocyclic compound | |
| IL286677A (en) | New compounds and their pharmaceutical preparations for the treatment of inflammatory disorders | |
| IL286688A (en) | New compounds and their pharmaceutical preparations for the treatment of inflammatory disorders | |
| BR112021023765A2 (pt) | Composto de fórmula (1), um isômero óptico, uma forma cristalina ou um sal farmaceuticamente aceitável do mesmo, inibidor de aurora quinase, composição farmacêutica de combinação e aplicação do composto | |
| NZ764004A (en) | Heteroaryl compounds as muscarinic m1 receptor positive allosteric modulators | |
| IL277553A (en) | Preparations for the treatment of neurodegenerative diseases by continuous administration | |
| IL286685A (en) | New compounds and their pharmaceutical preparations for the treatment of inflammatory disorders | |
| BR112021025236A2 (pt) | Composto, composição farmacêutica, uso do composto, e, método para a profilaxia ou o tratamento de fibrose, distúrbios dermatológicos, dor, doenças proliferativas malignas, benignas, doenças respiratórias, distúrbios do sistema nervoso central, doenças cardiovasculares, distúrbios inflamatórios, obesidade ou resistência à insulina | |
| IL285751A (en) | New compounds and their pharmaceutical preparations for the treatment of diseases | |
| MX2014000855A (es) | Moduladores receptores de glucagon de quinolinilo. | |
| EP3845230A4 (en) | PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION | |
| MX2021014544A (es) | Derivados de aminoglucosidos antibacterianos. | |
| NZ775905A (en) | Pyrrolo-pyridazine derivatives as muscarinic m1 receptor positive allosteric modulators | |
| GB201905536D0 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of metabolic disorders |